Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. - Archive ouverte HAL Access content directly
Journal Articles EMBO Molecular Medicine Year : 2013

Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.

(1) , (2) , (2) , (2) , (2) , (2, 3) , (2) , (2) , (2, 4) , (1) , (1) , (1) , (5) , (5) , (6) , (1) , (1) , (1) , (2, 7) , (8) , (2)
1
2
3
4
5
6
7
8
Anouk Emadali
  • Function : Author
  • PersonId : 944575
Carlo Petosa

Abstract

Immuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse. Using a transcriptome-powered targeted proteomics screen, we discovered a gene regulatory circuit involving the nuclear factor CYCLON which characterizes aggressive disease and resistance to the anti-CD20 monoclonal antibody, Rituximab, in high-risk B-cell lymphoma. CYCLON knockdown was found to inhibit the aggressivity of MYC-overexpressing tumours in mice and to modulate gene expression programs of biological relevance to lymphoma. Furthermore, CYCLON knockdown increased the sensitivity of human lymphoma B cells to Rituximab in vitro and in vivo. Strikingly, this effect could be mimicked by in vitro treatment of lymphoma B cells with a small molecule inhibitor for BET bromodomain proteins (JQ1). In summary, this work has identified CYCLON as a new MYC cooperating factor that autonomously drives aggressive tumour growth and Rituximab resistance in lymphoma. This resistance mechanism is amenable to next-generation epigenetic therapy by BET bromodomain inhibition, thereby providing a new combination therapy rationale for high-risk lymphoma.
Fichier principal
Vignette du fichier
emmm201202034.pdf (843.35 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-00852222 , version 1 (20-08-2013)

Identifiers

Cite

Anouk Emadali, Sophie Rousseaux, Juliana Bruder-Costa, Claire Rome, Samuel Duley, et al.. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.: CYCLON-induced Rituximab resistance. EMBO Molecular Medicine, 2013, 5 (8), pp.1180-95. ⟨10.1002/emmm.201202034⟩. ⟨inserm-00852222⟩
955 View
434 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More